BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14:409-414. [PMID: 22522501 DOI: 10.1038/aja.2011.150] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Nientiedt C, Budczies J, Endris V, Kirchner M, Schwab C, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, Schirmacher P, Hohenfellner M, Stenzinger A, Duensing S. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urol Oncol 2021:S1078-1439(21)00301-X. [PMID: 34325986 DOI: 10.1016/j.urolonc.2021.06.024] [Reference Citation Analysis]
2 Couñago F, López-Campos F, Díaz-Gavela AA, Almagro E, Fenández-Pascual E, Henríquez I, Lozano R, Linares Espinós E, Gómez-Iturriaga A, de Velasco G, Quintana Franco LM, Rodríguez-Melcón I, López-Torrecilla J, Spratt DE, Guerrero LL, Martínez-Salamanca JI, Del Cerro E. Clinical Applications of Molecular Biomarkers in Prostate Cancer. Cancers (Basel) 2020;12:E1550. [PMID: 32545454 DOI: 10.3390/cancers12061550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Hyatt C, McDougall C, Miller-Samuel S, Russo J. Genetic Counseling for Men with Prostate Cancer. Urol Clin North Am 2021;48:323-37. [PMID: 34210488 DOI: 10.1016/j.ucl.2021.03.004] [Reference Citation Analysis]
4 Nientiedt C, Endris V, Jenzer M, Mansour J, Sedehi NTP, Pecqueux C, Volckmar AL, Leichsenring J, Neumann O, Kirchner M, Hoveida S, Lantwin P, Kaltenecker K, Dieffenbacher S, Gasch C, Hofer L, Franke D, Tosev G, Görtz M, Schütz V, Radtke JP, Nyarangi-Dix J, Hatiboglu G, Simpfendörfer T, Schönberg G, Isaac S, Teber D, Koerber SA, Christofi G, Czink E, Kreuter R, Apostolidis L, Kratochwil C, Giesel F, Haberkorn U, Debus J, Sültmann H, Zschäbitz S, Jäger D, Duensing A, Schirmacher P, Grüllich C, Hohenfellner M, Stenzinger A, Duensing S. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. Urol Oncol 2020;38:637.e17-27. [PMID: 32280037 DOI: 10.1016/j.urolonc.2020.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Kgatle MM, Kalla AA, Islam MM, Sathekge M, Moorad R. Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy. Prostate Cancer 2016;2016:5653862. [PMID: 27891254 DOI: 10.1155/2016/5653862] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
6 Sanchez A, Schoenfeld JD, Nguyen PL, Fiorentino M, Chowdhury D, Stampfer MJ, Sesso HD, Giovannucci E, Mucci LA, Shui IM. Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis 2016;19:197-201. [PMID: 26926928 DOI: 10.1038/pcan.2016.4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mayer M, Selig K, Tüttelmann F, Dinkel A, Gschwend JE, Herkommer K. Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy. Fam Cancer 2019;18:221-30. [PMID: 30229510 DOI: 10.1007/s10689-018-0101-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R. Prostate Cancer Germline Variations and Implications for Screening and Treatment. Cold Spring Harb Perspect Med 2018;8:a030379. [PMID: 29101112 DOI: 10.1101/cshperspect.a030379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Titze U, Hansen T, Titze B, Schulz B, Gunnemann A, Rocco B, Sievert KD. Feasibility study for ex vivo fluorescence confocal microscopy (FCM) on diagnostic prostate biopsies. Quant Imaging Med Surg 2021;11:1322-32. [PMID: 33816171 DOI: 10.21037/qims-20-895] [Reference Citation Analysis]
10 Leão RRN, Price AJ, James Hamilton R. Germline BRCA mutation in male carriers-ripe for precision oncology? Prostate Cancer Prostatic Dis 2018;21:48-56. [PMID: 29242595 DOI: 10.1038/s41391-017-0018-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther 2021;228:107932. [PMID: 34174272 DOI: 10.1016/j.pharmthera.2021.107932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party. Hereditary prostate cancer - Primetime for genetic testing? Cancer Treat Rev 2019;81:101927. [PMID: 31783313 DOI: 10.1016/j.ctrv.2019.101927] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
13 Brandão A, Paulo P, Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Mol Sci 2020;21:E5036. [PMID: 32708810 DOI: 10.3390/ijms21145036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
14 Kao CH, Bishop KS, Xu Y, Han DY, Murray PM, Marlow GJ, Ferguson LR. Identification of Potential Anticancer Activities of Novel Ganoderma lucidum Extracts Using Gene Expression and Pathway Network Analysis. Genomics Insights 2016;9:1-16. [PMID: 27006591 DOI: 10.4137/GEI.S32477] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
15 Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, Heath E, Fridman R, Kim HR, Bonfil RD. Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth. Int J Cancer 2015;136:11-20. [PMID: 24798488 DOI: 10.1002/ijc.28948] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
16 Conran CA, Brendler CB, Xu J. Personalized prostate cancer care: from screening to treatment. Asian J Androl 2016;18:505-8. [PMID: 27184548 DOI: 10.4103/1008-682X.179529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Matejcic M, Patel Y, Lilyquist J, Hu C, Lee KY, Gnanaolivu RD, Hart SN, Polley EC, Yadav S, Boddicker NJ, Samara R, Xia L, Sheng X, Lubmawa A, Kiddu V, Masaba B, Namuguzi D, Mutema G, Job K, Henry DM, Ingles SA, Wilkens L, Le Marchand L, Watya S, Couch FJ, Conti DV, Haiman CA. Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry. JCO Precis Oncol 2020;4:32-43. [PMID: 32832836 DOI: 10.1200/po.19.00179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
18 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
19 Mikropoulos C, Goh C, Leongamornlert D, Kote-Jarai Z, Eeles R. Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. Future Oncol 2014;10:1679-94. [PMID: 25145435 DOI: 10.2217/fon.14.72] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
20 Evans O, Gaba F, Manchanda R. Population-based genetic testing for Women's cancer prevention. Best Pract Res Clin Obstet Gynaecol 2020;65:139-53. [PMID: 32245629 DOI: 10.1016/j.bpobgyn.2020.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
21 King B, McHugh J, Snape K. A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer. Appl Clin Genet 2021;14:255-66. [PMID: 34295175 DOI: 10.2147/TACG.S261737] [Reference Citation Analysis]
22 Whitaker H, Tam JO, Connor MJ, Grey A. Prostate cancer biology & genomics. Transl Androl Urol 2020;9:1481-91. [PMID: 32676435 DOI: 10.21037/tau.2019.07.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Helfand BT. A comparison of genetic risk score with family history for estimating prostate cancer risk. Asian J Androl 2016;18:515-9. [PMID: 27004541 DOI: 10.4103/1008-682X.177122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
24 Mcreynolds KM, Connors LM. Genomics of Prostate Cancer: What Nurses Need to Know. Seminars in Oncology Nursing 2019;35:79-92. [DOI: 10.1016/j.soncn.2018.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA. Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. J Clin Oncol 2020;38:1807-13. [PMID: 32208047 DOI: 10.1200/JCO.19.02808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
26 Gandhi J, Afridi A, Vatsia S, Joshi G, Joshi G, Kaplan SA, Smith NL, Khan SA. The molecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer Prostatic Dis 2018;21:22-36. [PMID: 29282359 DOI: 10.1038/s41391-017-0023-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
27 Olokpa E, Moss PE, Stewart LV. Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate. PPAR Res 2017;2017:9456020. [PMID: 29181019 DOI: 10.1155/2017/9456020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
28 Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer 2017;123:1912-24. [PMID: 28323334 DOI: 10.1002/cncr.30631] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
29 Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R. Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World J Gastrointest Oncol 2020;12:1456-63. [PMID: 33362915 DOI: 10.4251/wjgo.v12.i12.1456] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Roed Nielsen H, Petersen J, Therkildsen C, Skytte A, Nilbert M. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2. Acta Oncologica 2016;55:38-44. [DOI: 10.3109/0284186x.2015.1067714] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
31 Hunter SM, Rowley SM, Clouston D, Li J, Lupat R, Krishnananthan N, Risbridger G, Taylor R, Bolton D, Campbell IG, Thorne H; KCon Fab Investigators. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer. Urol Oncol 2016;34:120.e9-16. [PMID: 26585945 DOI: 10.1016/j.urolonc.2015.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Meissner VH, Strüh JGH, Kron M, Liesenfeld LA, Kranz S, Gschwend JE, Herkommer K. The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy. World J Urol 2020;38:3091-9. [PMID: 32161996 DOI: 10.1007/s00345-020-03147-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
33 Cardoso M, Maia S, Paulo P, Teixeira MR. Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis. Oncoscience 2016;3:288-96. [PMID: 28050579 DOI: 10.18632/oncoscience.322] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
34 Pilie PG, Giri VN, Cooney KA. HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl 2016;18:530-2. [PMID: 27034017 DOI: 10.4103/1008-682X.175785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Gorodetska I, Kozeretska I, Dubrovska A. BRCA Genes: The role in genome stability, cancer stemness and therapy resistance. J Cancer. 2019;10:2109-2127. [PMID: 31205572 DOI: 10.7150/jca.30410] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 22.0] [Reference Citation Analysis]
36 Song WH, Kim SH, Joung JY, Park WS, Seo HK, Chung J, Lee KH. Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review. J Korean Med Sci 2017;32:377-81. [PMID: 28049253 DOI: 10.3346/jkms.2017.32.2.377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
37 Maia S, Cardoso M, Pinto P, Pinheiro M, Santos C, Peixoto A, Bento MJ, Oliveira J, Henrique R, Jerónimo C, Teixeira MR. Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients. PLoS One 2015;10:e0132728. [PMID: 26176944 DOI: 10.1371/journal.pone.0132728] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
38 Cortesi L, Domati F, Guida A, Marchi I, Toss A, Barbieri E, Marcheselli L, Venturelli M, Piana S, Cirilli C, Federico M. BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees. Cancer Biol Med 2021:j. [PMID: 33710808 DOI: 10.20892/j.issn.2095-3941.2020.0481] [Reference Citation Analysis]
39 Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ, Vaszko T, Kasler M, Olah E, Balmaña J, Gutiérrez-Enríquez S, Diez O, Teulé A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L; EMBRACE., GEMO Study Collaborators., HEBON., KConFab Investigators. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol 2017;35:2240-50. [PMID: 28448241 DOI: 10.1200/JCO.2016.69.4935] [Cited by in Crossref: 91] [Cited by in F6Publishing: 35] [Article Influence: 22.8] [Reference Citation Analysis]
40 Mandigo AC, Knudsen KE. Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes. Clin Cancer Res 2020;26:1784-6. [PMID: 32019859 DOI: 10.1158/1078-0432.CCR-19-4033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Brandão A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Ukgpcs Collaborators, Schleutker J, Wang Y, Pashayan N, Batra J, Apcb BioResource, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, Southey MC, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, The Impact Study Steering Committee And Collaborators, Kogevinas M, Wiklund F, Penney KL, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Ruyck K, Razack A, Newcomb LF, Canary Pass Investigators, Lessel D, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, The Profile Study Steering Committee, The Practical Consortium, Teixeira MR. The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers (Basel) 2020;12:E3254. [PMID: 33158149 DOI: 10.3390/cancers12113254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Udager AM, Tomlins SA. Molecular Biomarkers in the Clinical Management of Prostate Cancer. Cold Spring Harb Perspect Med 2018;8:a030601. [PMID: 29311125 DOI: 10.1101/cshperspect.a030601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Kwon OK, Ha YS, Lee JN, Kim S, Lee H, Chun SY, Kwon TG, Lee S. Comparative Proteome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteogenomics. Cancer Genomics Proteomics 2019;16:273-86. [PMID: 31243108 DOI: 10.21873/cgp.20132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
44 Helfand BT, Catalona WJ. The Epidemiology and Clinical Implications of Genetic Variation in Prostate Cancer. Urologic Clinics of North America 2014;41:277-97. [DOI: 10.1016/j.ucl.2014.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
45 Gupta A, Shukla N, Nehra M, Gupta S, Malik B, Mishra AK, Vijay M, Batra J, Lohiya NK, Sharma D, Suravajhala P. A Pilot Study on the Whole Exome Sequencing of Prostate Cancer in the Indian Phenotype Reveals Distinct Polymorphisms. Front Genet 2020;11:874. [PMID: 33193569 DOI: 10.3389/fgene.2020.00874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
46 Tapia-laliena MA, Korzeniewski N, Hohenfellner M, Duensing S. High-risk prostate cancer: A disease of genomic instability. Urologic Oncology: Seminars and Original Investigations 2014;32:1101-7. [DOI: 10.1016/j.urolonc.2014.02.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
47 Nowacka-Zawisza M, Forma E, Walczak M, Różański W, Bryś M, Krajewska WM. Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer. Med Oncol 2015;32:246. [PMID: 26433958 DOI: 10.1007/s12032-015-0691-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Rasnic R, Brandes N, Zuk O, Linial M. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants. BMC Cancer 2019;19:783. [PMID: 31391007 DOI: 10.1186/s12885-019-5994-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
49 Kim SH, Park WS, Yun SI, Joo J, Joung JY, Seo HK, Chung J, Lee GK, Lee KH. Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy. Histopathology 2016;68:673-9. [DOI: 10.1111/his.12809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
50 Maylin ZR, Nicolescu RC, Pandha H, Asim M. Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease. Transl Oncol 2021;14:101115. [PMID: 33993099 DOI: 10.1016/j.tranon.2021.101115] [Reference Citation Analysis]
51 Green WJF, Ball G, Powe D. Does the molecular classification of breast cancer point the way for biomarker identification in prostate cancer? WJCU 2016;5:80. [DOI: 10.5410/wjcu.v5.i2.80] [Reference Citation Analysis]
52 Gnanapragasam VJ. Molecular markers to guide primary radical treatment selection in localized prostate cancer. Expert Review of Molecular Diagnostics 2014;14:871-81. [DOI: 10.1586/14737159.2014.936851] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
53 Yuan J, Strack PR, Toniatti C, Pelletier M. A zinc finger nuclease assay to rapidly quantitate homologous recombination proficiency in human cell lines. Anal Biochem 2013;434:96-8. [PMID: 23149234 DOI: 10.1016/j.ab.2012.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO. BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics 2017;37:1005-23. [PMID: 28548905 DOI: 10.1148/rg.2017160144] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
55 Li M, Mou Y, Hou S, Cao D, Li A. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report. Medicine (Baltimore) 2018;97:e13113. [PMID: 30407325 DOI: 10.1097/MD.0000000000013113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]